ClinicalTrials.gg

Program

albenatide

Also written as “CJC-1134-PC Injection” and “CJC-1134-PC”.

Its studies are mostly in Diabetes Mellitus, Type 2, led by 2 companies.

Furthest: phase 3, since Jun 18, 20254 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Changshan ConjuChem BioPharmaceutical Research and Development (Hebei)20 open or runningphase 3since Jun 18, 2025Jun 18, 2025none ahead
ConjuChem20 open or runningphase 2since Mar 13, 2008Mar 13, 2008none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 13, 2008First study: phase 2 study in Diabetes Mellitus, Type 2New to ConjuChemConjuChem · NCT00638716 · 122 enrolled · Canada
  2. Oct 20, 2011Phase 2 study in Diabetes Mellitus, Type 2ConjuChem · NCT01514149 · 73 enrolled · United States, Canada
  3. Jun 18, 2025Changshan ConjuChem BioPharmaceutical Research and Development (Hebei)'s first studies: 2 phase 3 studies in Type 2 Diabetes Mellitus - Poor ControlNew to Changshan ConjuChem BioPharmaceutical Research and Development (Hebei)Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) · NCT07058545, NCT07057271

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07057271Type 2 Diabetes Mellitus - Poor Control · China3CompletedChangshan ConjuChem BioPharmaceutical Research and Development (Hebei)Feb 21, 2023464
NCT07058545Type 2 Diabetes Mellitus - Poor Control · China3CompletedChangshan ConjuChem BioPharmaceutical Research and Development (Hebei)Feb 20, 2023474
NCT01514149Diabetes Mellitus, Type 2 · United States, Canada2TerminatedConjuChemMay 201273
NCT00638716Diabetes Mellitus, Type 2 · Canada2CompletedConjuChemNov 2008122

How it is read

Names in the registry

  • “CJC-1134-PC Injection”, 3 entries
  • “CJC-1134-PC”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.